Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

LEF-1 immunohistochemistry, a better diagnostic biomarker than β-catenin for medulloblastoma, WNT-activated subtyping

17 Jan 2024

Abstract excerpt

To the Editor: Medulloblastomas (MBs) are high-grade embryonal tumors of the cerebellum and the most frequent childhood malignant brain tumor. Four molecular groups (WNT-activated, SHH-activated, group 3, and group 4) defined in the World Health Organization (WHO) Classification of Tumours of the central nervous system have major risk stratification features that directly impact patient management, treatment...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Circular RNAs in diseases
Share to Glioma Diagnosis and Treatment
Share to Neuroblastoma Research and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38237134
DOI: 10.1093/jnen/nlad104

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

LEF-1 immunohistochemistry, a better diagnostic biomarker than β-catenin for medulloblastoma, WNT-activated subtypingPMID 38237134Read ↗

Medulloblastoma, WNT-activated/SHH-activated: clinical impact of molecular analysis and histogenetic evaluation.Semantic proximity Read ↗

Integrating Molecular Subclassification of Medulloblastomas into Routine Clinical Practice: A Simplified ApproachSemantic proximity Read ↗

Beta-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics.Semantic proximity Read ↗

Immunohistochemical Surrogates for Molecular Stratification in Medulloblastoma.Semantic proximity Read ↗

A CTNNB1-altered medulloblastoma shows the immunophenotypic, DNA methylation and transcriptomic profiles of SHH-activated, and not WNT-activated, medulloblastoma.Semantic proximity Read ↗

beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee.Semantic proximity Read ↗

Diagnostic Accuracy of a Reduced Immunohistochemical Panel in Medulloblastoma Molecular Subtyping, Correlated to DNA-methylation AnalysisSemantic proximity Read ↗

Update on the integrated histopathological and genetic classification of medulloblastoma – a practical diagnostic guidelineSemantic proximity Read ↗

Medulloblastoma: clinicopathological parameters, risk stratification, and survival analysis of immunohistochemically validated molecular subgroupsSemantic proximity Read ↗

Adult Medulloblastoma: Clinico-molecular Spectrum, An Institutional ExperienceSemantic proximity Read ↗

Affordable panel of techniques for prediction of molecular classification of a series of medulloblastomas in a reference pediatric hospital in ColombiaSemantic proximity Read ↗

Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.